Sonoma Pharmaceuticals Beheer
Beheer criteriumcontroles 3/4
Sonoma Pharmaceuticals' CEO is Amy Trombly, appointed in Sep 2019, has a tenure of 5.17 years. total yearly compensation is $726.54K, comprised of 44.7% salary and 55.3% bonuses, including company stock and options. directly owns 0.57% of the company’s shares, worth $21.42K. The average tenure of the management team and the board of directors is 3.1 years and 6.2 years respectively.
Belangrijke informatie
Amy Trombly
Algemeen directeur
US$726.5k
Totale compensatie
| Percentage CEO-salaris | 44.7% |
| Dienstverband CEO | 5.2yrs |
| Eigendom CEO | 0.6% |
| Management gemiddelde ambtstermijn | 3.1yrs |
| Gemiddelde ambtstermijn bestuur | 6.2yrs |
Recente managementupdates
Recent updates
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Oct 17
Market Cool On Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues Pushing Shares 33% Lower
Aug 27The Market Lifts Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Shares 75% But It Can Do More
Jul 12Investors Aren't Entirely Convinced By Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues
May 26Sonoma Pharmaceuticals GAAP EPS of -$0.29, revenue of $3.99M
Aug 11Does Sonoma Pharmaceuticals (NASDAQ:SNOA) Have A Healthy Balance Sheet?
Sep 30Sonoma Pharmaceuticals reports FQ2 results
Nov 20Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$5m |
| Mar 31 2024 | US$727k | US$325k | -US$5m |
| Dec 31 2023 | n/a | n/a | -US$5m |
| Sep 30 2023 | n/a | n/a | -US$6m |
| Jun 30 2023 | n/a | n/a | -US$6m |
| Mar 31 2023 | US$560k | US$319k | -US$5m |
| Dec 31 2022 | n/a | n/a | -US$7m |
| Sep 30 2022 | n/a | n/a | -US$6m |
| Jun 30 2022 | n/a | n/a | -US$5m |
| Mar 31 2022 | US$643k | US$318k | -US$5m |
| Dec 31 2021 | n/a | n/a | -US$6m |
| Sep 30 2021 | n/a | n/a | -US$5m |
| Jun 30 2021 | n/a | n/a | -US$5m |
| Mar 31 2021 | US$580k | US$300k | -US$5m |
| Dec 31 2020 | n/a | n/a | -US$3m |
| Sep 30 2020 | n/a | n/a | -US$4m |
| Jun 30 2020 | n/a | n/a | -US$5m |
| Mar 31 2020 | US$386k | US$153k | -US$4m |
Compensatie versus markt: Amy's total compensation ($USD726.54K) is about average for companies of similar size in the US market ($USD655.65K).
Compensatie versus inkomsten: Amy's compensation has increased whilst the company is unprofitable.
CEO
Amy Trombly (56 yo)
5.2yrs
Tenure
US$726,543
Compensatie
Ms. Amy M. Trombly, Esq. has been Chief Executive Officer of Sonoma Pharmaceuticals, Inc. since September 27, 2019 and serves as its President and also serves as its Director since July 22, 2022. She is a...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 5.2yrs | US$726.54k | 0.57% $ 21.4k | |
| Chief Financial Officer | 1.6yrs | US$307.46k | 0.32% $ 11.8k | |
| Executive VP | 4.6yrs | US$658.67k | 0.58% $ 21.5k | |
| Controller | 1.3yrs | US$479.59k | 0.056% $ 2.1k |
3.1yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren management: SNOA's management team is considered experienced (3.1 years average tenure).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 2.3yrs | US$726.54k | 0.57% $ 21.4k | |
| Lead Independent Director | 11.7yrs | US$65.00k | 0.020% $ 755.9 | |
| Independent Director | 6.2yrs | US$47.50k | 0% $ 0 | |
| Independent Director | 17.6yrs | US$55.00k | 0.021% $ 800.7 | |
| Scientific Advisory Board | 1.3yrs | geen gegevens | geen gegevens |
6.2yrs
Gemiddelde duur
70.5yo
Gemiddelde leeftijd
Ervaren bestuur: SNOA's board of directors are considered experienced (6.2 years average tenure).